Using a new eye-tracking platform to measure eye movement
Development and Validation of a Novel Eye-Tracking Software-based Platform to Extract Oculometric Measures
NeuraLight · NCT05476523
This study is testing a new eye-tracking system to see how well it measures eye movements in healthy people compared to a proven eye-tracker.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | NeuraLight (industry) |
| Locations | 1 site (Wilmington, Delaware) |
| Trial ID | NCT05476523 on ClinicalTrials.gov |
What this trial studies
This observational study aims to validate the NeuraLight system for capturing oculometric data from healthy participants. It involves enrolling individuals through convenience and snowball sampling methods, focusing on those who can provide informed consent. The study will compare the data captured by NeuraLight with that from a validated eye-tracker system, while also collecting data to optimize a regression model for predicting clinical outcomes in neurological patients.
Who should consider this trial
Good fit: Ideal candidates are healthy men and women aged 18 to 90 with normal or corrected vision who can follow instructions.
Not a fit: Patients with neurological diseases or a history of epilepsy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the accuracy of eye movement measurements, benefiting future neurological assessments.
How similar studies have performed: While the approach is innovative, similar studies have shown promise in utilizing eye-tracking technology for clinical assessments.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men and women ages between 18 and 90 years old * Normal or corrected vision * Ability to follow instructions * Willing and able to sign an informed consent form Exclusion Criteria: * Inability to sit for 20 minutes on a chair in a calm manner * Personal or 1st degree relative history of epilepsy * Additional neurological diseases * Drug or alcohol abuse
Where this trial is running
Wilmington, Delaware
- NeuraLight — Wilmington, Delaware, United States (RECRUITING)
Study contacts
- Principal investigator: Eitan Raveh, PhD — NeuraLight
- Study coordinator: Eitan Raveh, PhD
- Email: eitan@neuralight.ai
- Phone: +972-58-6277947
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Eye Movement